Drug intelligence / Profile preview

qingzhi capsules

Development stage: Unknown
Administration: Oral

Overview

**Qingzhi Capsules** is an oral traditional Chinese medicine formula containing rhubarb, goji berry, and cistanche. It is manufactured in China for primary hyperlipidemia associated with the traditional Chinese medicine pattern of liver-kidney yin deficiency with blood stasis; its labelled traditional actions are promoting blood circulation, resolving blood stasis, and nourishing the liver and kidneys. The product is a registered Chinese medicinal capsule rather than a target-defined single-molecule therapy, so a specific molecular mechanism has not been established. ([sinoways.com.cn](https://www.sinoways.com.cn/product/4.html))

Other names: 清脂胶囊QingZhiJiaoNang

Targets

PRKCD (Protein kinase C delta)ATF6 (Activating transcription factor 6 alpha)EIF2AK3 (Pkr-like endoplasmic reticulum kinase)

Beyond the preview

Go deeper on qingzhi capsules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on qingzhi capsules.

Explore the full profile